Pentagon mandates testosterone screening for soldiers aged 30+

Consensus Summary

US Defense Secretary Pete Hegseth announced a mandatory screening program for testosterone deficiency among active-duty and reserve military personnel aged 30 and above, effective this week. The policy, unveiled in a video titled 'the High-T Department of War,' requires annual testing for soldiers in that age group while allowing voluntary screening for those under 30. Hegseth framed the initiative as essential for maintaining combat readiness, stating that optimal testosterone levels would ensure troops perform at their 'absolute best' in the 'brutal and unrelenting' modern battlefield. The program also offers voluntary testosterone replacement therapy (TRT) for those found to have deficient levels, though medical experts have raised concerns about potential risks, including infertility and long-term health complications.

The policy emerges amid broader healthcare shifts under the Trump administration, including the repeal of the military’s flu vaccine mandate in April and efforts by Health Secretary Robert F Kennedy Jr to ease restrictions on testosterone prescriptions. Critics argue the move is inconsistent, as the Pentagon has simultaneously promoted TRT for cisgender soldiers while arguing that hormone treatment disqualifies transgender troops. A federal judge has already questioned these discrepancies, ordering the Pentagon to provide further justification by 7 August. The initiative also follows a 2022 study involving over 5,200 men aged 45 to 80, which found that while testosterone therapy reduced some heart risks, it increased rates of atrial arrhythmia and bone fractures.

Hegseth’s announcement has drawn sharp reactions from medical professionals, who argue that widespread screening lacks scientific backing and could lead to overtreatment. Doctors cited by the Guardian warned that testosterone levels naturally decline with age, particularly after 30, but screening all soldiers in that age group is unnecessary. Some experts suggested lifestyle changes—such as sleep, diet, and exercise—could address low testosterone without medical intervention. Meanwhile, the Pentagon has faced pressure to clarify whether the policy extends to female troops, given that testosterone therapy is not FDA-approved for women. Democratic lawmakers, including Senator Tammy Duckworth, have called for broader hormone screenings to address fertility issues among all service members, though Hegseth has historically opposed women in combat roles.

Coverage of the policy diverges in emphasis, with the Guardian focusing on the legal and medical controversies, including the judge’s order and expert warnings about TRT risks. ABC, meanwhile, highlights the political backlash from Democrats, who accuse Hegseth of aligning with fringe 'manosphere' ideologies, and notes the Navy’s drug-testing program for hormonal substances following a 2022 SEAL recruit death. The Guardian also details Hegseth’s history of blocking promotions for women and minorities in the military, while ABC underscores the broader cultural shift toward testosterone advocacy, including Kennedy Jr’s anti-aging claims. Both outlets agree that the policy lacks clear research support, but the Guardian places greater weight on the legal and gender-equity implications, whereas ABC frames it as part of a larger trend of hormone-related controversies in the military.

Unresolved questions remain about the policy’s implementation, including how abnormal test results will be evaluated and whether screenings will apply equally to male and female troops. The Guardian reports that the Pentagon has not provided detailed guidance on these issues, leaving room for further legal challenges and medical scrutiny. Meanwhile, the Trump administration’s broader healthcare agenda—such as easing testosterone prescription limits and repealing vaccine mandates—continues to spark debate. As the next court hearing approaches on 7 August, the Pentagon’s ability to justify the policy’s consistency with its stance on transgender troops will be closely examined, potentially shaping future military healthcare policies.